Zyversa Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ZVSA Nasdaq 8731 https://www.zyversa.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zyversa Therapeutics Inc

ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 13th, 2023 8:30 pm
ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200 - Mar 7th, 2023 2:20 pm
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference - Mar 1st, 2023 2:20 pm
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference - Feb 27th, 2023 2:20 pm
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury - Feb 23rd, 2023 2:20 pm
ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4) - Jan 27th, 2023 9:00 pm
ZyVersa Therapeutics to Present at BIO CEO & Investor Conference - Jan 25th, 2023 2:45 pm
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event - Jan 11th, 2023 7:45 pm
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th - Jan 11th, 2023 6:00 pm
ZyVersa Therapeutics Appoints Three New Board Members - Jan 5th, 2023 2:45 pm
ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200 - Jan 3rd, 2023 2:45 pm